For now, however, its still premature to administer prophylactic GLP-1 RAs to patients being treated with lithium. If the GLP-1 RAs can indeed be shown to be nephroprotective, it would affect the risk-benefit evaluation, where currently, many patients dont want to take lithium and many prescribers dont want to prescribe it, so many people who could potentially benefit could now consider it as a viable treatment option, Dr McIntyre said
In evoke/evoke+, not all biomarkers are expected to show robust changes in response to treatment, and alterations in A are not expected since semaglutide is not an A-directed agent
Sustainable change: The programs stepbystep guidance toward healthy lifestyle changes in nutrition, exercise, sleep, and stress management will help patients achieve longlasting results
Healthcare providers should discuss this likelihood during shared decision-making conversations, along with considerations of cost, insurance coverage, medication availability, and perioperative management (as these agents delay gastric emptying)